- Trials with a EudraCT protocol (680)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (126)

These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006). | |
Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records. |
Study title: DTPa-HBV-IPV-083 |
Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 41514 |
Study title: DTPa-HBV-IPV-088 |
Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 41518 |
Study title: DTPa-HBV-IPV-093 |
Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 41515 |
Study title: Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Leung TWT et al. Cancer, January 15, 2002, 421-7 |
Active substance: FLUOROURACIL |
Study summary document link (including results): |
View full study record |
Document reference: 28272 |
Study title: Fibrolamellar hepatocellular carcinoma in children and adolescents. Katzenstein HM et al. Cancer. 2003 Apr 15;97(8):2006-12 |
Active substance: FLUOROURACIL |
Study summary document link (including results): 12673731.pdf |
View full study record |
Document reference: 28303 |
Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication] |
Active substance: Mucosa compositum |
Study summary document link (including results): |
View full study record |
Document reference: 40075 |
Study title: Open Label, Multicenter, Phase IIIB, Follow up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis and Inactivated Poliovirus Antigens one Month after the 4th Hexavac® Vaccination in Healthy Children, who Participated in the NeisVac-C Non-Interference Study 216 |
Active substance: N. meningitidis group C polysaccharide conjugated to tetanus toxoid adsorbed on Al3+ |
Study summary document link (including results): |
View full study record |
Document reference: 41293 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43096 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43124 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43182 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43192 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43202 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43217 |
Study title: Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226.Chow PKH, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology 2002;36(5):1221-6 2002;(5):1221-1226. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43100 |
Study title: Hepatocellular carcinoma in children and adolescents: Results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. Katzenstein HM et al. J Clin Oncol. June 15, 2002, 2789-97 |
Active substance: FLUOROURACIL |
Study summary document link (including results): 12065555.pdf |
View full study record |
Document reference: 28270 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43227 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43237 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43247 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43319 |
Study title: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcninoma. Zhang Z, Wu M, Liu Q. Chin J Oncol. July 6, 1999, 214-6 |
Active substance: FLUOROURACIL |
Study summary document link (including results): |
View full study record |
Document reference: 28279 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: JMeza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: J |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43328 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43337 |
Study title: Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17.Meza-Junco J, Montano-Loza A, Candelaria M. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Gastroenterologia y Hepatologia 27(1)()(pp 11-17), 2004 Date of Publication: Jan 2004 2004;(1):11-17. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43347 |
Study title: Open label, randomised comparative assessment of the immunogenicity and reactogenicity of SmithKline Beecham's (SB's) diphteria/tetanus/acellular pertussis (DTPa) vaccine and SB's Hib with commercially available diphtheria/tetanus/whole cell pertussis (DTPw) and SB's Hib. Vaccines to be combined in the same syringe and administered to healthy infants as three consecutive doses at 2, 3 and 4 months of age. |
Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
Study summary document link (including results): |
View full study record |
Document reference: 41137 |
Study title: EUV07: A phase III, open, randomized, controlled, primary vaccination study to assess the immunogenicity and the safety of CP20/20/5/3DT-IPV-PRP~T and ACTAcel given concomitantly with OPV vaccine and TETRAct-Hib given concomitantly with OPV vaccine at 6, 10, 14 weeks of age. All infants receiving hepatitis B vaccine (Recomvax B) at 0, 6, 14 weeks of age EUV06: Safety and immunogenicity of hepatitis B vaccine distributed by Aventis Pasteur Korea administered at 0-1-6 months when given in association with three Aventis Pasteur pertussis combination (1 whole cell and 2 acellular) vaccines administered at 2, 4 and 6 months in Mexican infants |
Active substance: Hepatitis B Surface Antigen |
Study summary document link (including results): |
View full study record |
Document reference: 47181 |
Study title: Clinical study to assess the immunological memory induced by a primary course using different formulations of Hib conjugate vaccines in several combinations with acellular pertussis vaccines by giving one dose of unconjugated PRP co-administered with SB Biologicals¿ DTPa-HBV combined vaccine at 12-24 months of age in infants primed in study DTPa-HBV-037. |
Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
Study summary document link (including results): |
View full study record |
Document reference: 41146 |
Study title: Open, randomised, clinical study to evaluate the interference on the immunogenicity of vaccine antigens, when Haemophilus influenzae type b tetanus conjugate and combined diphtheria, tetanus, acellular pertussis vaccines are co-administered, either in one single or two separate injections as a primary vaccination course to healthy infants at 2, 4 and 6 months of age. |
Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
Study summary document link (including results): |
View full study record |
Document reference: 41136 |
Study title: Open clinical study to assess the safety of SmithKline Beecham Biologicals' Haemophilus influenzae type b conjugate vaccine mixed with SmithKline Beecham Biologicals' diphtheria, tetanus, tricomponent acellular pertussis vaccine and administered in one single injection, given as a primary vaccination course to healthy infants at 3, 4 and 5 months of age. |
Active substance: Haemophilus influenzae type b capsular polysaccharide (PRP) conjugated to tetanus toxoid (TT) |
Study summary document link (including results): |
View full study record |
Document reference: 41132 |
Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, whole-cell pertussis, poliomyelitis vaccine (TETRACOQ®) given as a second booster to 4- to 7-year-old children |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41193 |
Study title: Comparative safety and immunogenicity study of diphtheria, tetanus, acellular pertussis, poliomyelitis vaccine (DTacP-IPV) and diphtheria, tetanus, poliomyelitis vaccine (DT POLIO®) administered as a booster in children aged 8 to 12 years |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41197 |
Study title: Concomitant administration of a Haemophilus influenzae type b - Hepatitis b vaccine with a diphtheria, tetanus, acellular pertussis, inactivated polio combination vaccine in healthy infants |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41191 |
Study title: Diminution of the anti-polyribosylribito phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae Type b vaccine by concurrent inactivated poliovirus vaccination |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41205 |
Study title: Large scale safety study of the DTacP-IPV {acellular TETRACOQ®) vaccine, administered in combination (one injection site) or in assocation two injection sites) with Haemophilus influenzae Type b vaccine (Act-HIB®) for primary and booster immunisation |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41203 |
Study title: Randomised open trial of the safety and the immunogenicity of a combined dihtheria, tetanus, acellular pertussis and inactivated polio vaccine (DTacP-IPV) mixed with Haemophilus influenzae type b vaccine (Act-HIB®) given either at 3-5 and 12 or 2-4-6 and 13 months of age |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41190 |
Study title: Safety and immunogenicity of a diphteria, tetanus, acellular pertussis, enhanced inactivated trivalent poliovirus vaccine administered separately or combined with Haemophilus influenzae type b vaccine, to healthy Chilean infants |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41188 |
Study title: Safety and immunogenicity of PMSV diphtheria, tetanus, acellular pertussis, polio (DTacP-IPV) vaccine given mixed or separately with Haemophilus influenzae type b (Act-HIB®) vaccine, as a primary series. Comparison of three lots of DTacP-IPV vaccine given combined or separately with Act-HIB® |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41189 |
Study title: Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen-to nineteen-month-old infants |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 41192 |
Study title: Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129)Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization. ; Guan-Y-S. World Journal of Gastroenterology, 15 JUL 2004, Vol/Iss/Pg. 10/14 (2127-2129) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30291 |
Study title: Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56)Successful left hepatectomy for hepatocellular carcinoma in a child after transcatheter arterial chemoembolization: Report of a survival. ; Uemura-S, T. European Journal of Pediatric Surgery, 1993, Vol /Iss/Pg. 3/1 (54-56) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30327 |
Study title: Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267)Hepatocellular carcinoma after transcatheter hepatic arterial embolization: A histopathologic study of 84 resected cases. Higuchi-T. Cancer , 1994, Vol/Iss/Pg. 73/9 (2259-2267) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30258 |
Study title: Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. ;Jin-Wook-Chung, J. American Journal of Roentgenology, 1995, Vol/Iss/Pg. 165/2 (315-321)Hepatocellular carcinoma and portal vein invasion: Results of treatment with transcatheter oily chemoembolization. ;Jin-Wook-Chung, J. American Journal of Roentgenology, 1995, Vol/Iss/Pg. 165/2 (315-321) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30259 |
Study title: Hepatocellular carcinoma outcomes based on indicated treatment strategy. ; Rose-A-T. American Surgeon, 1998, Vol/Iss/Pg. 64/12 (1128-1135)Hepatocellular carcinoma outcomes based on indicated treatment strategy. ; Rose-A-T. American Surgeon, 1998, Vol/Iss/Pg. 64/12 (1128-1135) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30260 |
Study title: The role and limitation of living donor liver transplantation for hepatocellular carcinoma. ; Lo-C-M. Liver Transplantation, 2004, Vol/Iss/Pg. 10/3 (440-447)The role and limitation of living donor liver transplantation for hepatocellular carcinoma. ; Lo-C-M. Liver Transplantation, 2004, Vol/Iss/Pg. 10/3 (440-447) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30333 |
Study title: A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B(12) binding capacity in a young Japanese female. ; Kanai-T. Japanese Journal of Clinical Oncology, 01 JUN 2004, Vol/Iss/Pg. 34/6 (346-351)A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B(12) binding capacity in a young Japanese female. ; Kanai-T. Japanese Journal of Clinical Oncology, 01 JUN 2004, Vol/Iss/Pg. 34/6 (346-351) |
Active substance: IOBITRITOL |
Study summary document link (including results): |
View full study record |
Document reference: 30213 |
Study title: Extrahepatic metastases of hepatocellular carcinoma; KATYAL S; Radiology; 2000 vol.216 p.698 703Extrahepatic metastases of hepatocellular carcinoma; KATYAL S; Radiology; 2000 vol.216 p.698 703 |
Active substance: IOVERSOL |
Study summary document link (including results): |
View full study record |
Document reference: 30411 |
Study title: Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. ; Izumi-R. Hepato-Gastroenterology, 1996, Vol/Iss/Pg. 43/12 (1415-1420)Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma. ; Izumi-R. Hepato-Gastroenterology, 1996, Vol/Iss/Pg. 43/12 (1415-1420) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30304 |
Study title: Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. ;Czauderna-P. Pediatric Blood and Cancer, 2006, Vol/Iss/Pg. 46/7 (825-828)Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. ;Czauderna-P. Pediatric Blood and Cancer, 2006, Vol/Iss/Pg. 46/7 (825-828) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30306 |
Study title: Preoperative Chemoembolization for Hepatocellular Carcinoma.02/12/2010Mario Morino. Journal of Surgical Oncology Supplement 3:91-93 (1993)Preoperative Chemoembolization for Hepatocellular Carcinoma.02/12/2010Mario Morino. Journal of Surgical Oncology Supplement 3:91-93 (1993) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30307 |
Study title: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. ; Lau-W-Y. Lancet, 06 MAR 1999, Vol/Iss/Pg. 353/9155 (797-801)Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. ; Lau-W-Y. Lancet, 06 MAR 1999, Vol/Iss/Pg. 353/9155 (797-801) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30218 |
Study title: Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? ; Ngan-H. British Journal of Radiology, 1990, Vol/Iss/Pg. 63/754 (771-775)Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? ; Ngan-H. British Journal of Radiology, 1990, Vol/Iss/Pg. 63/754 (771-775) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30281 |
Study title: Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series. ; Lucena-de-la-Poza-J-L. Transplantation Proceedings, 2002, Vol/Iss/Pg. 34/1 (260-261)Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series. ; Lucena-de-la-Poza-J-L. Transplantation Proceedings, 2002, Vol/Iss/Pg. 34/1 (260-261) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30282 |
Study title: Pulmonary embolism: A fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma. ;Czauderna-P. Journal of Pediatric Surgery, 2005, Vol/Iss/Pg. 40/10 (1647-1650)Pulmonary embolism: A fatal complication of arterial chemoembolization for advanced hepatocellular carcinoma. ;Czauderna-P. Journal of Pediatric Surgery, 2005, Vol/Iss/Pg. 40/10 (1647-1650) |
Active substance: IODINE |
Study summary document link (including results): |
View full study record |
Document reference: 30315 |
Study title: Safety of four acellular pertussis combination vaccines (Infantrix-IPV, Boostrix, Covaxis and repevax) given a booster dose to six-year-old Finnish children |
Active substance: purif tetan toxoid,purif dipht toxoid,purif pert toxoid,purif filamentous haemaggl,purif fimbriae (agglutinogens 2 & 3),purif pertactin (69kda membrane protein)-inact polio vacc |
Study summary document link (including results): |
View full study record |
Document reference: 41433 |
Study title: Safety and immunogenicity of acellular pertussis combined with tetanus and diphtheria toxoids adsorbed and inactivated poliomyelitis vaccine (TdcP-IPV) in adolescents and adults compared to Td-mlPV and cP given separately in adolescents and compared to TdcP or Td given separately with IPV or cP in adults |
Active substance: Inactivatd Poliomyelitis Vaccine (Vero cells) (40/8/32) |
Study summary document link (including results): |
View full study record |
Document reference: 21208 |
Study title: Liver transplantation in the therapy of hepatocellular carcinoma: A revision of our series. |
Active substance: Ethyl esters of iodized fatty acids of poppy seed oil |
Study summary document link (including results): |
View full study record |
Document reference: 39920 |
Study title: Wiedermann D, Widermannova D, Lokaj J. Scripta Medica [Czech edition from Brno]. 1986; 59(7):415-424. Several parameters of cellular and humoral immune function in children with recurrent respiratory infections treated with Isoprinosine®.Wiedermann D, Widermannova D, Lokaj J. Scripta Medica [Czech edition from Brno]. 1986; 59(7):415-424. Several parameters of cellular and humoral immune function in children with recurrent respiratory infections treated with Isoprinosine®. |
Active substance: INOSINE |
Study summary document link (including results): |
View full study record |
Document reference: 30177 |
Study title: Lipiodol computerized tomography: How sensitive and specific is the technique in the diagnosis of hepatocellular carcinoma? |
Active substance: Ethyl esters of iodized fatty acids of poppy seed oil |
Study summary document link (including results): |
View full study record |
Document reference: 39899 |
Study title: Open Study to determine the concentration of telithromycin in the extracellular and intracellular compartments of middle ear fluid in children with acute otitis media or otitis media with spontaneous effusion after single oral administration of a telithromycin pediatric suspension |
Active substance: telithromycin |
Study summary document link (including results): |
View full study record |
Document reference: 41567 |
Study title: Clin Nucl Med. 1995 Jul;20(7):601-4. Detection of a 2.1 cm hepatocellular carcinoma in an 11-year-old boy by Tl-201 chloride. Case presentation and correlative imaging findings. Kempf JS, Abdel-Dayem H. Clin Nucl Med. 1995 Jul;20(7):601-4. Detection of a 2.1 cm hepatocellular carcinoma in an 11-year-old boy by Tl-201 chloride. Case presentation and correlative imaging findings. Kempf JS, Abdel-Dayem H. |
Active substance: THALLIUM 201T1 CHLORIDE |
Study summary document link (including results): |
View full study record |
Document reference: 44553 |
Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication] |
Active substance: Lymphomyosot - Tropfen |
Study summary document link (including results): |
View full study record |
Document reference: 40057 |
Study title: Comparative study of an acellular (P.M.sv.) and a whole cell (Wellcome) Pertussis vaccines com bined with Diphtheria and Tetanus vaccines in healthy infants according to 2 schedules in the U.K. |
Active substance: Diphtheria, Tetanus, Acellular Pertussis and inactivated Poliomyelitis Vaccine, adsorbed. |
Study summary document link (including results): |
View full study record |
Document reference: 41410 |
Study title: DTPa-HBV-IPV-103 |
Active substance: diphtheria, tetanus, acellular pertussis, hepatitis b recombinant (adsorbed), inactivated poliovirus, adsorbed conjugated haemophilus influenzae type b vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 41516 |
Study title: A phase II, open-label, randomized, single-center, comparative study evaluating safety, tolerability and immunogenicity of three vaccinations of the DTPHib combined vaccine (Chiron Vaccines; now Novartis Vaccines) in comparison to separate vaccinations of DTP (Chiron Behring; now Novartis Vaccines) and Hib/AlPO4 (Chiron Vaccines; now Novartis Vaccines) vaccines, when administered to 2, 3, 4 months old healthy infants. |
Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 48393 |
Study title: A phase II, open-label, single-centre, singal-arm, extension study to evaluate the safety and immunogenicity of a booster vaccination of the DTPHib combined vaccine (Chiron Vaccines; now Novartis Vaccines) administered to 18-20 months old healthy infants who had previously received either DTPHib combined vaccine or separate administrations of DTP (Chiron Behring; now Novartis Vaccines) and Hib/AlPO4 (Chiron Vaccines; now Novartis Vaccines) vaccines at 2, 3 and 4 months of age. |
Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine |
Study summary document link (including results): |
View full study record |
Document reference: 48394 |
Study title: Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. Treatment modalities in patients with hepatocellular carcinoma: A retrospective series in a single institution in Mexico. [Spanish]. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43268 |
Study title: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. |
Active substance: TAMOXIFEN |
Study summary document link (including results): |
View full study record |
Document reference: 43274 |